Back to search

Article

ENDORSE: a prognostic model for endocrine therapy response in advanced estrogen-receptor positive breast cancers

2021-02-05

Abstract excerpt

<h4>ABSTRACT</h4> Endocrine therapy remains the primary treatment for advanced and metastatic estrogen receptor-positive (ER+) breast cancers. Patients who progress on endocrine therapy may benefit from add-on treatment targeting the PI3K/MTOR signaling pathways or by switching to chemotherapy. However, these options are only available after progression on first-line treatment with endocrine therapy. In the absenc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7084133d-04fb-5e95-9745-e81de1d35e8f
DOI
10.1101/2021.02.03.21251035
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
ENDORSE: a prognostic model for endocrine therapy response in advanced estrogen-receptor positive breast cancersDOI 10.1101/2021.02.03.21251035
Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.Semantic proximity
THR-6E: A Six-Gene Cell-of-Origin Signature Stratifies Risk and Predicts Systemic Therapy Response in ER+/HER2− Breast CancerSemantic proximity
A novel gene signature to predict response to neoadjuvant chemotherapy and endocrine treatment in estrogen receptor-positive breast cancer patientsSemantic proximity
Secondary Transcriptomic Analysis of Triple Negative Breast Cancer Reveals Reliable Universal and Subtype-Specific BiomarkersSemantic proximity
Novel Gene Signatures Predictive of Patient Recurrence-free Survival in HR+HER2- Breast CancerSemantic proximity
EstroGene2.0: A multi-omic database of response to estrogens, ER-modulators, and resistance to endocrine therapies in breast cancerSemantic proximity
Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy ResponseSemantic proximity
A novel twelve-gene signature to evaluate neoadjuvant chemotherapy response and predict prognosis in breast cancerSemantic proximity
Retrospective multi-cohort validation of a real-world transcriptomics-guided machine learning model for treatment response prediction in breast cancerSemantic proximity
MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patientsSemantic proximity
Integrated single-cell and bulk RNA sequencing analysis identifies the predictive signature for prognosis and neoadjuvant chemotherapy responses in breast cancerSemantic proximity
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast CancerSemantic proximity
Select a neighboring publication to make it the new centre.